15/12/20 AMAG Pharmaceuticals : Files Submission in Response to the Food and Drug Administration's Notice of Opportunity for a Hearing and Proposal to Withdraw Approval of Makena AQ
14/12/20 AMAG Pharmaceuticals : Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection) PU
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
17/11/20 AMAG PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modifica (form 8-K) AQ
16/11/20 AMAG Pharmaceuticals : Covis Group Completes Acquisition of AMAG Pharmaceuticals AQ
Manager TitleAgeSince
Director of Finance/CFO - -
President 52 -
Corporate Secretary - -
Director TitleAgeSince
Director/Board Member 52 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
11/16/20 A Issuer sale

Chairman

136,253 0.3949%
11/16/20 A
Caligan Partners LP
Issuer saleCompany 3,499,428 10.1425%
11/16/20 A Issuer sale

Chief Executive Officer

1,000,000 2.8983%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.29% - - 477M
+1.97%+1.43%+48.44%+158.18% 1,037B
+1.42%+3.72%+53.32%+51.55% 615B
+1.43%+0.99%+34.83%+79.44% 448B
+5.14%+5.84%+37.54%+27.28% 326B
+1.85%+4.64%+38.53%+39.87% 293B
-0.11%+0.97%+22.57%+17.81% 264B
+0.25%-3.10%-24.44%-42.25% 216B
+1.49%-0.02%+20.14%+57.80% 198B
+0.40%-3.99%+15.23%+68.50% 162B
Average +1.44%+1.12%+27.35%+50.91% 395.27B
Weighted average by Cap. +1.68%+1.47%+36.34%+75.89%
Logo AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.
Employees
-
  1. Stock Market
  2. Stocks
  3. AMAG Stock